Fixed price, unfixed volume: the company is locked into a rate while the amount it can sell against it is climbing
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes a situation where the price/rate/fee is already fixed or contractually set, while the quantity of business at that rate is currently rising or about to rise, and the reported results reflect the lower volume level. Let's analyze the transcript. The call is about Primerica's Q3 2016 results. Key segments: Term Life insurance and Investment and Savings Products (ISP). Also corporate. Look for any mention of fixed rates, contracts, or fees that are set, and volume increasing. In the Term Life segment, they discuss adjusted direct premiums growing 13% due to strong sales. They mention "YRT reinsurance rate reductions" and "coinsurance transactions" from IPO. They talk about "adjusted direct premiums should naturally grow over the next several years by a minimum of 10% annually as a result of the coinsurance transactions we entered into at the time of the IPO." Also, "Beginning in 2017 insurance policies coming to the end of their first policy term, will no longer be ceded to the IPO reinsurers. We expect this change to increase net premiums by approximately $50 million by the end of 2017." This is about retention of policies, not about a fixed rate per unit. The rate is the premium, which is set by the policy terms. But is that a fixed rate? The premiums are set at policy issuance, but the volume is the number of policies. However, the question is about a situation where the price/rate/fee is already fixed and the quantity is rising. Here, the premium per policy is fixed at issuance, but the company is adding new policies at new rates? Actually, the policies are level term, so the premium is fixed for the term. But the company is selling new policies, so the rate is not the same across all policies. The question is about a meaningful part of the business where the rate is already settled and volume is rising. The transcript does not explicitly say that the rate is fixed and volume is rising in a way that the reported results understate future results. They talk about growth in policies issued, but that is volume at current rates. The rate is not the open variable; it's the volume.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
ABR · Q4 2016 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing the Agency Business servicing portfolio at $13.6 billion with a fixed 48 basis point weighted average servicing fee that is already contracted and recurring. They explicitly note the portfolio is growing through recent originations, including $700 million closed in December, which will drive higher servicing income in Q 1. Management states they expect the portfolio to generate over $65 million annually and references growth from 2015 levels, indicating the reported Q4 results reflect a lower average volume during the quarter while the settled economics now scale with the increasing volume arriving in Q1.
FIX · Q1 2017 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing a situation where pricing is stable and contracts (backlog) lock in rates, while volume is rising through backlog growth and upcoming organic work. The Q1 results reflect lower seasonal volume, with the backlog supporting higher throughput ahead. This fits the criteria of settled rates on meaningful contracted business with 13% backlog increase driving volume step-up.
CHE · Q3 2022 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES Management describes Medicare reimbursement rates as already fixed by regulation (CMS), with the volume side now rising through a first significant expansion of clinical staff and patient capacity since the pandemic, plus strengthening admissions and weekly ADC growth in the second half. The reported quarter reflects lower volume (ADC down 4.